Bromo-DragonFLY

Bromo-DragonFLY
	1-(4-Bromofuro[2,3-f][1]benzofuran-8-il)propan-2-amin
Drugi nazivi	Bromo-benzodifuranil-izopropilamin
Identifikacija
CAS registarski broj	502759-67-3
PubChem	9839057, ; 10544447 R, ; 10496688 S
ChemSpider	8014776 , 8719838 R , 8672089 S
ChEMBL	CHEMBL149024
Jmol-3D slike	Slika 1; Slika 2
SMILES
	CC(N)Cc1c2ccoc2c(Br)c2ccoc12 CC(N)CC1=C2OC=CC2=C(Br)C2=C1C=CO2
InChI
	InChI=1S/C13H12BrNO2/c1-7(15)6-10-8-2-4-17-13(8)11(14)9-3-5-16-12(9)10/h2-5,7H,6,15H2,1H3 ; Kod: GIKPTWKWYXCBEC-UHFFFAOYSA-N
Svojstva
Molekulska formula	C13NH12O2Br
Molarna masa	294,144 g mol−1
log P	2,519
	(šta je ovo?) (verifikuj) ; Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
	Infobox references

Bromo-DragonFLY je psihodelični lek koji je srodan sa fenetilaminskom familijom. Bromo-DragonFLY se smatra ekstremno potentnim halucinogenom, skoro je potenta kao LSD. Njegova normal doza je u opsegu 200 μg do 800 μg. On ima veoma dugo vreme trajanja, i do nekoliko dana.^[6] On je nedozvoljena supstanca u Finskoj, Švedskoj,^[7] Norveškoj i Danskoj. Bromo-DragonFLY sadrži stereocentar i R-(-)-bromo-DragonFLY je aktivniji stereoizomer.

Farmakologija

Halucinogeno dejstvo bromo-DragonFLY je posredovan njegovom agonistnim dejstvom na 5-HT_2A serotoninski receptor. Bromo-DragonFLY isto tako ima visok afinitet vezivanja za 5-HT_2B i 5-HT_2C serotoninske receptora, te je neselektivni 5-HT₂ agonist.^[8]^[9]

Reference

↑ „Bromo-DragonFLY”. Forendex. USA: Southern Association of Forensic Scientists. Arhivirano iz originala na datum 2014-10-06. Pristupljeno 16. 3. 2012.
↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ „Erowid Bromo-DragonFly Vault : Dosage”.
↑ „Svensk författningssamling (SFS) - Riksdagen”. Arhivirano iz originala na datum 2012-05-28.
↑ Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE (December 1998). „A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor”. Journal of Medicinal Chemistry 41 (26): 5148–9. DOI:10.1021/jm9803525. PMID 9857084.
↑ Corazza O, Schifano F, Farre M, Deluca P, Davey Z, Torrens M, Demetrovics Z, Di Furia L, Flesland L, Siemann H, Skutle A, Van Der Kreeft P, Scherbaum N. Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. Current Clinical Pharmacology. 2011 May;6(2):125-9. PMID 21592070

Literatura

'A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT_2A receptor' J. Med. Chem. 41(26): 5148-5149
'Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT_2A/2C receptor agonists' by J. J. Chambers, D. M. Kurrasch-Orbaugh, M. A. Parker, and D. E. Nichols in J. Med. Chem. 44(6): 1003-1010 (2001) DOI:10.1021/jm000491y

Povezano

Spoljašnje veze

Portal Hemija

[1] „Bromo-DragonFLY”. Forendex. USA: Southern Association of Forensic Scientists. Arhivirano iz originala na datum 2014-10-06. Pristupljeno 16. 3. 2012.

[2] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[3] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[4] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[titleErowid_Bromo-Dragonfly_Vault_:_Dosage-6] „Erowid Bromo-DragonFly Vault : Dosage”.

[titleSvensk_författningssamling_(SFS)_-_Riksdagen-7] „Svensk författningssamling (SFS) - Riksdagen”. Arhivirano iz originala na datum 2012-05-28.

[pmid9857084-8] Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE (December 1998). „A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor”. Journal of Medicinal Chemistry 41 (26): 5148–9. DOI:10.1021/jm9803525. PMID 9857084.

[9] Corazza O, Schifano F, Farre M, Deluca P, Davey Z, Torrens M, Demetrovics Z, Di Furia L, Flesland L, Siemann H, Skutle A, Van Der Kreeft P, Scherbaum N. Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. Current Clinical Pharmacology. 2011 May;6(2):125-9. PMID 21592070

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

Bromo-DragonFLY

Sadržaj

Farmakologija

Reference

Literatura

Povezano

Spoljašnje veze

Navigacija

Bromo-DragonFLY

Farmakologija

Reference

Literatura

Povezano

Spoljašnje veze

Navigacija

Pretraga